Company Overview
Protara Therapeutics, Inc. operates as a clinical-stage biopharmaceutical company dedicated to advancing transformative therapies designed for the treatment of cancer and rare diseases. The company focuses its research and development efforts primarily on its lead program, TARA-002, which is an investigational cell therapy currently undergoing Phase II clinical trials for the treatment of non-malignant conditions, though the full description cuts off at "non-m". This enterprise functions within the broader Healthcare sector, specifically targeting the highly specialized and capital-intensive Biotechnology industry, which is characterized by significant regulatory hurdles and long development timelines. In terms of scale, the company holds a market capitalization of $287.19M, employs a workforce of 46 individuals, and currently reports no available revenue figures for the trailing twelve months. The absence of reported revenue combined with a market cap of $287.19M indicates that the company is in a pre-commercialization phase where value is derived entirely from intellectual property and clinical potential rather than current sales performance.
Financial Health
The financial statements for the trailing twelve months show revenue as N/A, a net income of $-57,439,000, and an EBITDA of $-64,187,000. The substantial negative net income relative to the unavailable revenue figure reveals a cost structure dominated by research and development expenses and operational burn typical of clinical-stage entities that have not yet generated commercial sales. The company generated free cash flow of $-38,476,124, which signifies a continuous consumption of cash reserves required to fund ongoing clinical trials and operational overhead before product launch. All three margin metrics—Gross Margin, Operating Margin, and Profit Margin—are reported at 0.0%, indicating that the company has not yet achieved profitability or scaled revenue operations to cover its direct and operating costs. The balance sheet shows a cash position of $155.55M against total debt of $3.36M, resulting in a debt-to-equity ratio of 1.71, which suggests a leveraged capital structure despite the minimal absolute debt load. Liquidity is exceptionally strong with a current ratio of 14.58, meaning the company possesses more than fourteen times the current assets necessary to cover its short-term liabilities. Return on Equity stands at -31.6% and Return on Assets is -20.6%, metrics that reflect the dilution of equity and the heavy asset-light nature of biotechnology where returns are negative until a product reaches market approval.
Valuation Assessment
Valuation metrics for Protara Therapeutics present a mixed picture due to the lack of traditional earnings. The trailing P/E Ratio (TTM) is listed as N/A because there are no positive earnings to calculate a multiple against, while the Forward P/E is reported as -3.82, which reflects the expectation of continued negative earnings in the near term based on projected financial models. The Price to Book ratio is 1.45, suggesting that the market values the company at 1.45 times its book value, a premium that likely accounts for the intangible value of its clinical-stage pipeline and potential future commercialization prospects. Alternative valuation measures include a Price to Sales ratio of N/A due to the absence of revenue data, and an EV/EBITDA of -2.10, which further underscores the company's current burn rate and lack of operational profitability. The stock has traded within a 52-week range with a high of $7.82 and a low of $2.77, placing the current valuation context relative to this historical volatility band. The Beta value is 1.44, indicating that the stock price is expected to be 44% more volatile than the broader market, a characteristic common in small-cap biotechnology stocks where price movements are driven by clinical trial data and regulatory milestones rather than earnings reports.
Growth & Income
Protara Therapeutics currently exhibits N/A for Revenue Growth (YoY) and N/A for Earnings Growth (YoY), as the company has not yet established a recurring revenue stream or reported positive earnings in recent periods. Since there are no earnings to compare against revenue, the concept of earnings growing faster or slower than revenue is not applicable at this stage of the company's lifecycle. The company does not pay a dividend, evidenced by a Dividend Yield of N/A and a Payout Ratio of 0.0%, meaning the company reinvests all available capital, including its substantial cash reserves, back into its research programs and clinical operations. The overall growth and income profile is defined entirely by the potential for future commercialization rather than current financial expansion or income generation.